Follow us:

Microsoft Pri0

Welcome to Microsoft Pri0: That's Microspeak for top priority, and that's the news and observations you'll find here from Seattle Times technology reporter Matt Day.

June 28, 2007 at 9:17 AM

Koronis raises $20M in VC round

Koronis Pharmaceuticals said this morning it received $20 million in venture financing from Pacific Horizon Ventures and the Asset Management Co.

The Redmond-based biotechnology company said it plans to use the money to conduct two clinical trials on the effectiveness of its leading product candidate, a novel anti-HIV treatment in humans. Koronis expects to conclude the trials in 2008.

The therapy, already determined to be safe in humans, has shown effectiveness in a lab setting during pre-clinical trials, the privately held company said.

It seeks to anihilate HIV infections by encouraging mutations that make the virus unfit to reproduce. The company said Tuesday that it was enrolling patients in the first trial.

Comments | More in Biotechnology

COMMENTS

No personal attacks or insults, no hate speech, no profanity. Please keep the conversation civil and help us moderate this thread by reporting any abuse. See our Commenting FAQ.



The opinions expressed in reader comments are those of the author only, and do not reflect the opinions of The Seattle Times.


The Seattle Times

The door is closed, but it's not locked.

Take a minute to subscribe and continue to enjoy The Seattle Times for as little as 99 cents a week.

Subscription options ►

Already a subscriber?

We've got good news for you. Unlimited seattletimes.com content access is included with most subscriptions.

Subscriber login ►
The Seattle Times

To keep reading, you need a subscription upgrade.

We hope you have enjoyed your complimentary access. For unlimited seattletimes.com access, please upgrade your digital subscription.

Call customer service at 1.800.542.0820 for assistance with your upgrade or questions about your subscriber status.

The Seattle Times

To keep reading, you need a subscription.

We hope you have enjoyed your complimentary access. Subscribe now for unlimited access!

Subscription options ►

Already a subscriber?

We've got good news for you. Unlimited seattletimes.com content access is included with most subscriptions.

Activate Subscriber Account ►